Today’s Top Three in Pharma 012809

Astellas makes a big to acquire CV Therapeutics. Japan’s Astellas Pharma is offering a billion dollars in cash for CV Therapeutics. The bid comes in at $16 a share, a whopping 41 percent premium over yesterday’s close.

Abilify as an add-on therapy for depression – not everyone is convinced.

Watson‘s topical Overactive Bladder gel (Gelnique) gets FDA approval.

PLUS – Amylin hurting. Abbott‘s Vicodin CR delay means 200 layoffs. And Feds say, “Enough with the off-label promotion already!”

—––

Subscribe to the Impactiviti blog via e-mail

Subscribe to the Impactiviti blog via RSS

Impactiviti is a pharma consultancy focused on helping pharma/biotech/medical devices companies identify optimal vendors for training/marketing needs. This “matchmaking” service is provided free to clients.